Literature DB >> 22008916

Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice.

Kai Qiu1, Darin J Falk, Paul J Reier, Barry J Byrne, David D Fuller.   

Abstract

Pompe disease is a form of muscular dystrophy due to lysosomal storage of glycogen caused by deficiency of acid α-glucosidase (GAA). Respiratory failure in Pompe disease has been attributed to respiratory muscle dysfunction. However, evaluation of spinal tissue from Pompe patients and animal models indicates glycogen accumulation and lower motoneuron pathology. We hypothesized that restoring GAA enzyme activity in the region of the phrenic motor nucleus could lead to improved breathing in a murine Pompe model (the Gaa(-/-) mouse). Adeno-associated virus serotype 5 (AAV5), encoding either GAA or green fluorescent protein (GFP), was delivered at the C(3)-C(4) spinal level of adult Gaa(-/-) mice and the spinal cords were harvested 4 weeks later. AAV5-GAA injection restored spinal GAA enzyme activity and GAA immunostaining was evident throughout the cervical ventral horn. The periodic acid Schiff (PAS) method was used to examine neuronal glycogen accumulation, and spinal PAS staining was attenuated after AAV5-GAA injection. Lastly, plethysmography revealed that minute ventilation was greater in unanesthetized AAV5-GAA versus AAV5-GFP treated Gaa(-/-) mice at 1-4 months postinjection. These results support the hypothesis that spinal cord pathology substantially contributes to ventilatory dysfunction in Gaa(-/-) mice and therefore requires further detailed evaluation in patients with Pompe disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22008916      PMCID: PMC3255594          DOI: 10.1038/mt.2011.214

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  43 in total

1.  Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease.

Authors:  Mary Rucker; Thomas J Fraites; Stacy L Porvasnik; Melissa A Lewis; Irene Zolotukhin; Denise A Cloutier; Barry J Byrne
Journal:  Development       Date:  2004-06       Impact factor: 6.868

2.  Glycogen disease resembling mongolism, cretinism, and amytonia congenita; case report and review of literature.

Authors:  D H CLEMENT; G C GODMAN
Journal:  J Pediatr       Date:  1950-01       Impact factor: 4.406

3.  Use of the muscle volume analyzer to evaluate enzyme replacement therapy in late-onset Pompe disease.

Authors:  Fuminobu Sugai; Yosuke Kokunai; Yoichi Yamamoto; Goichi Hashida; Kengo Shimazu; Masahito Mihara; Satoru Inoue; Saburo Sakoda
Journal:  J Neurol       Date:  2009-11-12       Impact factor: 4.849

4.  Recombinant adeno-associated virus vector: use for transgene expression and anterograde tract tracing in the CNS.

Authors:  N L Chamberlin; B Du; S de Lacalle; C B Saper
Journal:  Brain Res       Date:  1998-05-18       Impact factor: 3.252

5.  Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2.

Authors:  C Martini; G Ciana; A Benettoni; F Katouzian; G M Severini; R Bussani; B Bembi
Journal:  Neurology       Date:  2001-09-11       Impact factor: 9.910

6.  Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors.

Authors:  Cathryn Mah; Christina A Pacak; Kerry O Cresawn; Lara R Deruisseau; Sean Germain; Melissa A Lewis; Denise A Cloutier; David D Fuller; Barry J Byrne
Journal:  Mol Ther       Date:  2007-01-23       Impact factor: 11.454

7.  Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.

Authors:  Thomas J Fraites; Mary R Schleissing; R Andrew Shanely; Glenn A Walter; Denise A Cloutier; Irene Zolotukhin; Daniel F Pauly; Nina Raben; Paul H Plotz; Scott K Powers; Paul D Kessler; Barry J Byrne
Journal:  Mol Ther       Date:  2002-05       Impact factor: 11.454

Review 8.  Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease).

Authors:  Nina Raben; Paul Plotz; Barry J Byrne
Journal:  Curr Mol Med       Date:  2002-03       Impact factor: 2.222

9.  Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.

Authors:  P S Kishnani; D Corzo; M Nicolino; B Byrne; H Mandel; W L Hwu; N Leslie; J Levine; C Spencer; M McDonald; J Li; J Dumontier; M Halberthal; Y H Chien; R Hopkin; S Vijayaraghavan; D Gruskin; D Bartholomew; A van der Ploeg; J P Clancy; R Parini; G Morin; M Beck; G S De la Gastine; M Jokic; B Thurberg; S Richards; D Bali; M Davison; M A Worden; Y T Chen; J E Wraith
Journal:  Neurology       Date:  2006-12-06       Impact factor: 9.910

Review 10.  Pompe disease in infants and children.

Authors:  Priya Sunil Kishnani; R Rodney Howell
Journal:  J Pediatr       Date:  2004-05       Impact factor: 4.406

View more
  23 in total

Review 1.  An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.

Authors:  Aditi Korlimarla; Jeong-A Lim; Priya S Kishnani; Baodong Sun
Journal:  Ann Transl Med       Date:  2019-07

Review 2.  Pompe Disease: From Basic Science to Therapy.

Authors:  Lara Kohler; Rosa Puertollano; Nina Raben
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

3.  Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease.

Authors:  Adrian G Todd; Jessica A McElroy; Robert W Grange; David D Fuller; Glenn A Walter; Barry J Byrne; Darin J Falk
Journal:  Ann Neurol       Date:  2015-06-30       Impact factor: 10.422

Review 4.  The respiratory neuromuscular system in Pompe disease.

Authors:  David D Fuller; Mai K ElMallah; Barbara K Smith; Manuela Corti; Lee Ann Lawson; Darin J Falk; Barry J Byrne
Journal:  Respir Physiol Neurobiol       Date:  2013-06-21       Impact factor: 1.931

Review 5.  Progress and challenges of gene therapy for Pompe disease.

Authors:  Giuseppe Ronzitti; Fanny Collaud; Pascal Laforet; Federico Mingozzi
Journal:  Ann Transl Med       Date:  2019-07

6.  Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease.

Authors:  Allison M Keeler; Marina Zieger; Sophia H Todeasa; Angela L McCall; Jennifer C Gifford; Samantha Birsak; Sourav R Choudhury; Barry J Byrne; Miguel Sena-Esteves; Mai K ElMallah
Journal:  Hum Gene Ther       Date:  2018-07-25       Impact factor: 5.695

Review 7.  Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem.

Authors:  Shannon L Macauley
Journal:  Pediatr Endocrinol Rev       Date:  2016-06

Review 8.  Pompe disease: literature review and case series.

Authors:  Majed Dasouki; Omar Jawdat; Osama Almadhoun; Mamatha Pasnoor; April L McVey; Ahmad Abuzinadah; Laura Herbelin; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

9.  Transcriptome assessment of the Pompe (Gaa-/-) mouse spinal cord indicates widespread neuropathology.

Authors:  S M F Turner; D J Falk; B J Byrne; D D Fuller
Journal:  Physiol Genomics       Date:  2016-09-09       Impact factor: 3.107

10.  B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease.

Authors:  Melissa E Elder; Sushrusha Nayak; Shelley W Collins; Lee Ann Lawson; Jeffry S Kelley; Roland W Herzog; Renee F Modica; Judy Lew; Robert M Lawrence; Barry J Byrne
Journal:  J Pediatr       Date:  2013-04-16       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.